Additionally, the subgroup differences between hetrombopag and the classical TPO-RAs, eltrombopag and romiplostim, was statistically significant (P = 0.038 and P = 0.007, respectively), suggesting that hetrombopag might be a preferable choice when there is suspicion of thrombosis in patients requiring treatment with TAs. The gene discussed is TPO; the disease is deep vein thrombosis.